Catheter Precision Inc. (NYSE American: VTAK) Stoc
Post# of 9
(Total Views: 73)
Posted On: 06/26/2024 12:35:02 PM
Catheter Precision Inc. (NYSE American: VTAK) Stock Volume Soars with Middle East Expansion of VIVO 3D Heart Imaging System
https://thestreetreports.com/catheter-precisi...ng-system/
The United States-based medical device company Catheter Precision Inc. (NYSE American: VTAK) gained significant attention on June 20 after announcing its first purchase order from Qatar. In the news release, Catheter Precision revealed that an initial evaluation of its VIVO product was conducted earlier in 2024 at the Hamad Medical Corporation Heart Hospital in Doha.
Catheter Precision Inc. (NYSE American: VTAK) surged 5.28% on June 25, 2024, with trading volume hitting 3.09 times the norm hitting an intraday high of $0.7199. The stock climbed an additional 4% in after-hours trading and boasts a 28.9% increase since June 20, 2024. VTAK’s trading volumes have seen a notable uptick since June 11, 2024, positioning it in breakout territory, surpassing its 20, 50, and 200-day moving averages. With numerous bullish indicators consistently present, VTAK is an attractive buy during sideways market movements or on dips, as its strong trend is expected to continue this upward trajectory for a while.
Catheter Precision’s VIVO (View Into Ventricular Onset) is a revolutionary non-invasive 3D imaging system that helps physicians identify the origin of ventricular arrhythmias before heart procedures. VIVO streamlines ventricular ablation, saving time and reducing complications. The company, following its expansion strategy, had previously announced this innovation. The company is renowned for its two key innovative products: VIVO™, aiding in ventricular arrhythmia source detection pre-procedure, and LockeT, a closure retention device. Read Entire Update Now!
These innovative medical devices, develops cutting-edge products aimed at enhancing patient care for physicians and hospitals. By collaborating with medical professionals, Catheter Precision improves its groundbreaking technologies and existing products, making workflows more efficient and reducing heart procedure times and potential complications. Their product, which received marketing clearance from the U.S. FDA and CE mark approval for the European Union, exemplifies their commitment to elevating healthcare standards.
Featured by Barchart alongside GameStop Corp (NYSE: GME), AMC Entertainment (NYSE: AMC), Novavax (NASDAQ: NVAX), Peraso (NASDAQ: PRSO), Intelligent Bio Solutions Inc (NASDAQ: INBS), Dyadic International Inc. (NASDAQ: DYAI) see: https://www.barchart.com/story/news/26816026/...i-vtak-amc
https://thestreetreports.com/catheter-precisi...ng-system/
The United States-based medical device company Catheter Precision Inc. (NYSE American: VTAK) gained significant attention on June 20 after announcing its first purchase order from Qatar. In the news release, Catheter Precision revealed that an initial evaluation of its VIVO product was conducted earlier in 2024 at the Hamad Medical Corporation Heart Hospital in Doha.
Catheter Precision Inc. (NYSE American: VTAK) surged 5.28% on June 25, 2024, with trading volume hitting 3.09 times the norm hitting an intraday high of $0.7199. The stock climbed an additional 4% in after-hours trading and boasts a 28.9% increase since June 20, 2024. VTAK’s trading volumes have seen a notable uptick since June 11, 2024, positioning it in breakout territory, surpassing its 20, 50, and 200-day moving averages. With numerous bullish indicators consistently present, VTAK is an attractive buy during sideways market movements or on dips, as its strong trend is expected to continue this upward trajectory for a while.
Catheter Precision’s VIVO (View Into Ventricular Onset) is a revolutionary non-invasive 3D imaging system that helps physicians identify the origin of ventricular arrhythmias before heart procedures. VIVO streamlines ventricular ablation, saving time and reducing complications. The company, following its expansion strategy, had previously announced this innovation. The company is renowned for its two key innovative products: VIVO™, aiding in ventricular arrhythmia source detection pre-procedure, and LockeT, a closure retention device. Read Entire Update Now!
These innovative medical devices, develops cutting-edge products aimed at enhancing patient care for physicians and hospitals. By collaborating with medical professionals, Catheter Precision improves its groundbreaking technologies and existing products, making workflows more efficient and reducing heart procedure times and potential complications. Their product, which received marketing clearance from the U.S. FDA and CE mark approval for the European Union, exemplifies their commitment to elevating healthcare standards.
Featured by Barchart alongside GameStop Corp (NYSE: GME), AMC Entertainment (NYSE: AMC), Novavax (NASDAQ: NVAX), Peraso (NASDAQ: PRSO), Intelligent Bio Solutions Inc (NASDAQ: INBS), Dyadic International Inc. (NASDAQ: DYAI) see: https://www.barchart.com/story/news/26816026/...i-vtak-amc
(0)
(0)Catheter Precision Inc (VTAK) Stock Research Links
Scroll down for more posts ▼